Med. praxi. 2010;7(1):28-31

Practical aspects of the eye effection of diabetics

MUDr.Eva Rencová
Oční klinika Fakultní nemocnice a LF UK v Hradci Králové

Diabetic retinopathy (DR) is the main cause of blindness in the working population. The aim of paper is to improve the cooperation

between diabetologists and ophthalmologists to avoid DR and its complications. In patients with the diabetes mellitus type 2 (DM2)

an ophthalmological examination should be indicated by a diabetologist or a general practitioner immediately after the diagnosis.

An ophthalmologist evaluates a tendency to the development of diabetic macular oedema (DME) and recommends a statin therapy and

or with direct macular photocoagulation (in the case of clinical significantly macular edema – CSME). In patients with the diabetes mellitus

type 1 (DM1), early retinal changes occur 5 years on the average after the diagnosis of diabetes is confirmed. In the case of advanced

nonproliferative or proliferative diabetic retinopathy an ophthalmologist performs the laser panretinophotocoagulation in prevent in

of the development of the proliferative diabetic retinopathy with its complications serious for the visual acuity. Accurate timing of joint

effort by a diabetologist and an ophthalmologist may prevent blindness development related to the diabetic retinopathy.

diabetologists with ophthalmologists.

Keywords: diabetic eye disease, diabetic retinopathy, macular edema, fenofibrate, laser photocoagulation, timing of cooperation of

Published: April 22, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rencová E. Practical aspects of the eye effection of diabetics. Med. praxi. 2010;7(1):28-31.
Download citation

References

  1. Dodson PM. Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality? Eye 2009; 23: 997-1003. Go to original source... Go to PubMed...
  2. Rencová E, Havel E, Novák J, et al. Dystrofické změny pigmentového epitelu v makule jako následek exsudativní diabetické makulopatie. Čs. Oftalmol. 1996; 52: 291-296.
  3. Nunes S, Pires I, Rosa A, et al. Microaneurysm turnover is a biomarker for diabetic retinopathy progression to clinically significant macular edema: findings for type 2 diabetics with nonproliferative retinopathy. Ophthalmologica 2009; 223: 292-297. Go to original source... Go to PubMed...
  4. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. ETDRS report. No I. Arch. Ophthalmol. 1985; 103: 1798-1806. Go to original source...
  5. Dodson PM. Diabetic Retinopathy: screening to treatment. Oxford diabetes library. Oxford University Press, 2008. Go to original source...
  6. Maja OO Jr., Takahashi BS, Costa RA, et al. Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: One years results of a randomized clinical trial. Amer. Journ. of Ophthalmol. 2009; 147(2): 291-297. Go to original source... Go to PubMed...
  7. Perušičová J, et al. Diabetické makroangiopatie a mikroangiopatie. Praha: Galén, 2003.
  8. Hamilton AMP, Ulbig MW, Polkinhorne P. Management of diabetic retinopathy. London: BMJ, 1996.
  9. Sosna T, Bouček P, Fišer I. Diabetická retinopatie. Jiří Cendelín: Praha, 2001.
  10. Kalvodová B, Reslová D, et al. Léčba floridní diabetické retinopatie panretinální fotokoagulací a časnou vitrektomií. Čs. Oftalmol. 2000; 56: 223-229.




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.